Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SLC6A9 | P48067 | 11/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378333 | 0.88 | NPC1 (0.58) | RAB9AMAPTSLC6A9NPC1KCNH2 | |
| SCHEMBL1380238 | 0.87 | MAPT (0.56) | RAB9AMAPTALDH1A1MAPK1SLC6A9 | |
| SCHEMBL1376779 | 0.85 | TP53 (0.65) | RAB9AMAPTMEN1ALDH1A1MAPK1 | |
| SCHEMBL4057516 | 0.83 | SLC2A1 (0.53) | RAB9AMAPTSLC6A9KCNH2MITF | |
| SCHEMBL1378682 | 0.83 | SLC6A9 (0.55) | RAB9ASLC6A9NPC1KCNH2 | |
| SCHEMBL2828643 | 0.82 | SLC6A9 (0.60) | SLC6A9KCNH2 | |
| SCHEMBL2832146 | 0.81 | SLC6A9 (0.56) | SLC6A9KCNH2 | |
| SCHEMBL4424875 | 0.80 | SLC6A9 (0.63) | SLC6A9KCNH2 | |
| SCHEMBL4237863 | 0.79 | SLC6A9 (0.64) | SLC6A9KCNH2 | |
| SCHEMBL4055390 | 0.79 | SLC6A9 (0.64) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101072762-B | Phenyl-piperazin methanone derivatives | HOFFMANN LA ROCHE | 2010-06-23 | — | — | CN | claimed |
| EP-1828154-B1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | EP | claimed |
| CN-101072762-A | Phenyl-piperazin methanone derivatives | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | CN | claimed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | claimed |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | US | claimed |
| CN-101072762-B | Phenyl-piperazin methanone derivatives | HOFFMANN LA ROCHE | 2010-06-23 | — | — | CN | disclosed |
| EP-1828154-B1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| CN-101072762-A | Phenyl-piperazin methanone derivatives | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | CN | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | GRIK5, GRM5, GRIN2C | RAB9A 2886/4885MAPT 975/4885MEN1 1682/4885 |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HTR5A, NPY5R, GRM5 | RAB9A 2935/4885MAPT 1153/4885MEN1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.